Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Overview of the Current Advancements and Trends in the Transungual Drug Delivery System

Author(s): Kajol Sharma, Vivek Yadav, Jurnal Reang, Kalicharan Sharma, Rajiv Kumar Tonk, Priti Jain and Surajpal Verma*

Volume 21, Issue 8, 2024

Published on: 04 April, 2023

Page: [1316 - 1324] Pages: 9

DOI: 10.2174/1570180820666230306140637

Price: $65

conference banner
Abstract

Background: Drug delivery across human nails is termed a transungual drug delivery system. It is recommended for the amelioration of nail disorders and infectious nail diseases like onychomycosis. Thereby, vivid anti-fungal regimens have been prescribed in the form of different types of formulations, including nail lacquers, nail film, nail paint, and other types for treating onychomycosis.

Methods: All the formulations currently marketed or being marketed for the transungal drug delivery system were thoroughly studied, compared, and evaluated for their advantages and disadvantages so that a new vision can be sustained along the path of creating newer anti-fungal transunguals, keeping in mind the anatomy of the nail and various parameters that govern bioavailability of active pharmaceutical ingredients across the nail bed. Accordingly, different techniques are devised to enhance permeation across the nail. The various parameters used to evaluate these formulations depend upon their physical, chemical, and mechanical properties.

Conclusion: The recent approaches in transungual novel drug delivery systems have been reported while exemplifying a few patented and marketed formulations, along with the clinical trial status of these formulations. There is a need for the development of new techniques to overcome all the loopholes present in the ongoing treatment techniques and the formulations used nowadays for the treatments of diseases that occur in nails. After thoroughly detailing transungal novel drug delivery systems, we envisage great opportunities for the researchers to carry out novel work in chemotherapy through nails.

« Previous Next »
Graphical Abstract

[1]
Christi, J.M.; Aundhia, C.; Seth, A.; Shah, N.; Kondhia, D.; Patel, S. Review on transungual drug delivery system. IAJPR, 2017, 7, 686-706.
[2]
Nadkar, S.; Lokhande, C. Current trends in novel drug delivery - An OTC perspective. Pharm. Times, 2010, 42, 17-23.
[3]
Saner, M.V.; Kulkarni, A.D.; Pardeshi, C.V. Insights into drug delivery across the nail plate barrier. J. Drug Target., 2014, 22(9), 769-789.
[http://dx.doi.org/10.3109/1061186X.2014.929138] [PMID: 24964054]
[4]
Schons, K.R.R.; Knob, C.F.; Murussi, N.; Beber, A.A.C.; Neumaier, W.; Monticielo, O.A. Nail psoriasis: a review of the literature. An. Bras. Dermatol., 2014, 89(2), 312-317.
[http://dx.doi.org/10.1590/abd1806-4841.20142633] [PMID: 24770509]
[5]
Singal, A.; Arora, R. Nail as a window of systemic diseases. Indian Dermatol. Online J., 2015, 6(2), 67-74.
[http://dx.doi.org/10.4103/2229-5178.153002] [PMID: 25821724]
[6]
Goldberg, I.; Fruchter, D.; Meilick, A.; Schwartz, M.E.; Sprecher, E. Best treatment practices for pachyonychia congenita. J. Eur. Acad. Dermatol. Venereol., 2014, 28(3), 279-285.
[http://dx.doi.org/10.1111/jdv.12098] [PMID: 23363249]
[7]
Shah, S.; Boen, M.; Kenner-Bell, B.; Schwartz, M.; Rademaker, A.; Paller, A.S. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol., 2014, 150(2), 146-153.
[http://dx.doi.org/10.1001/jamadermatol.2013.6448] [PMID: 24132595]
[8]
Micali, G.; Lacarrubba, F.; Stinco, G.; Argenziano, G.; Neri, I. Atlas of pediatric dermatoscopy; Springer International Publishing: Heidelberg, Germany, 2018.
[http://dx.doi.org/10.1007/978-3-319-71168-3]
[9]
Godic, A. Darier disease. A review of pathophysiological mechanisms. Acta Dermatovenerologica APA., 2003, 12, 119-126.
[10]
Piraccini, B.; Starace, M. Nail Disorders.In: Atlas of Pediatric Dermatoscopy; Springer International Publishing: Heidelberg, Germany, 2018, pp. 175-194.
[http://dx.doi.org/10.1007/978-3-319-71168-3_25]
[11]
Baars, M.P.; Pasch, M.C. Yellow-nail syndrome. Ned. Tijdschr. Dermatol. Venereol., 2014, 24, 657-658.
[12]
Preston, A.; Altman, K.; Walker, G. Yellow nail syndrome. Proc. Bayl. Univ. Med. Cent., 2018, 31(4), 526-527.
[http://dx.doi.org/10.1080/08998280.2018.1487662] [PMID: 30949001]
[13]
Patel, R.P.; Naik, S.A.; Patel, N.A.; Suthar, A.M. Drug delivery across human nail. Int. J. Curr. Pharm. Res., 2009, 1, 1-7.
[14]
Georgopapadakou, N. Discontinued drugs in 2005: anti-infectives. Expert Opin. Investig. Drugs, 2007, 16(1), 1-10.
[http://dx.doi.org/10.1517/13543784.16.1.1] [PMID: 17155849]
[15]
Kumar, T.P.; Raju, P.N. Transungual drug delivery: A promising route to treat nail disorders. Int. J. Pharma Res. Rev., 2013, 2, 22-33.
[16]
Alam, G.; Singh, M.P.; Singh, A.; Vishwakarma, D.K.; Patel, R.; Srivastava, S.P. Trans-ungual drug transport: advancement and challenges. J. Pharm. Res., 2012, 5, 2574-2579.
[17]
Lohani, B.; Kumar, G. Medicated nail lacquers-for effective treatment of nail disorders. Indo Am. J. Pharm. Sci., 2018, 5, 1392-1403.
[18]
Murdan, S. Drug delivery to the nail following topical application. Int. J. Pharm., 2002, 236(1-2), 1-26.
[http://dx.doi.org/10.1016/S0378-5173(01)00989-9] [PMID: 11891066]
[19]
Roberts, D.T.; Taylor, W.D.; Boyle, J. Guidelines for treatment of onychomycosis. Br. J. Dermatol., 2003, 148(3), 402-410.
[http://dx.doi.org/10.1046/j.1365-2133.2003.05242.x] [PMID: 12653730]
[20]
Sharma, N.; Sharma, D. An upcoming drug for onychomycosis. Tavaborole. J. Pharmacol. Pharmacother., 2015, 6(4), 236-239.
[http://dx.doi.org/10.4103/0976-500X.171870] [PMID: 26816482]
[21]
Morrison, P.W.; Khutoryanskiy, V.V. Therapeutic Delivery. Ther. Deliv., 2014, 5, 1297-1314.
[http://dx.doi.org/10.4155/tde.14.75] [PMID: 25531930]
[22]
Arun, R.R.; Kurian, N. Formulation and evaluation of transungual drug delivery of fluconazole using permeation enhancers screened by hydration of nail plate. Res. Rev. J. Pharm. Sci., 2017, 8, 32-45.
[23]
Thatai, P.; Sapra, B. Transungual delivery: deliberations and creeds. Int. J. Cosmet. Sci., 2014, 36(5), 398-411.
[http://dx.doi.org/10.1111/ics.12142] [PMID: 24888698]
[24]
Joshi, M.; Sharma, V.; Pathak, K. Nail psoriasis: An updated review of clinical reports on therapy and formulation aspects for topical delivery. J. Drug Deliv. Sci. Technol., 2015, 30, 63-73.
[http://dx.doi.org/10.1016/j.jddst.2015.09.017]
[25]
Akhtar, N.; Sharma, H.; Pathak, K. Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals. Scientifica (Cairo), 2016, 2016, 1-12.
[http://dx.doi.org/10.1155/2016/1387936] [PMID: 27123362]
[26]
Nandini, P.; Prasanthi, N.L.; Kiran, S.S.M.; Rao, N.R. A review on transungual drug delivery system. World J. Pharm. Pharm. Sci., 2018, 7, 260-269.
[27]
Tamburic, S.; Craig, D.Q.M. A comparison of different in vitro methods for measuring mucoadhesive performance. Eur. J. Pharm. Biopharm., 1997, 44(2), 159-167.
[http://dx.doi.org/10.1016/S0939-6411(97)00073-8]
[28]
Coviello, T.; Trotta, A.M.; Marianecci, C.; Carafa, M.; Di Marzio, L.; Rinaldi, F.; Di Meo, C.; Alhaique, F.; Matricardi, P. Gel-embedded niosomes: Preparation, characterization and release studies of a new system for topical drug delivery. Colloids Surf. B Biointerfaces, 2015, 125, 291-299.
[http://dx.doi.org/10.1016/j.colsurfb.2014.10.060] [PMID: 25524220]
[29]
Mahtab, A.; Anwar, M.; Mallick, N.; Naz, Z.; Jain, G.K.; Ahmad, F.J. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech, 2016, 17(6), 1477-1490.
[http://dx.doi.org/10.1208/s12249-016-0488-0] [PMID: 26857516]
[30]
Chauhan, M.K.; Verma, A. Spanlastics-future of drug delivery and targeting. World J. Pharm. Res., 2017, 6, 429-446.
[31]
Poojary, S. Topical antifungals: A review and their role in current management of dermatophytoses. Clin. Dermatol. Rev., 2017, 1(3), 24.
[http://dx.doi.org/10.4103/CDR.CDR_34_17]
[32]
Dhamoon, R.K.; Popli, H.; Gupta, M. Novel drug delivery strategies for the treatment of onychomycosis. Pharm. Nanotechnol., 2019, 7(1), 24-38.
[http://dx.doi.org/10.2174/2211738507666190228104031] [PMID: 31092174]
[33]
Soliman, G.M. Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. Int. J. Pharm., 2017, 523(1), 15-32.
[http://dx.doi.org/10.1016/j.ijpharm.2017.03.019] [PMID: 28323096]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy